Bio's for psoriasis show stable long-term effectiveness

[Fred]

This study looked at 10 years of real-world data on the effectiveness of biological treatments for psoriasis.

Quote:

---

Background:
Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real-world data on the effectiveness of biological treatment.

Objectives:
To analyse the long-term real-world outcome data of patients who are biologically naïve with moderate-to-severe psoriasis after switching to biological treatment.

Methods:
An observational study of patients who are biologically naïve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) values were analysed at 3–5 months, 6–11 months and at least once after ≥ 1 year, up to 9 years after the switch to biological treatment.

Results:
In total, 583 patients fulfilled the inclusion criteria. Of these, 399, 395 and 373 patients had observed outcome data beyond 1 year on the PASI, DLQI and EQ-5D, respectively, and 164, 168 and 152, respectively, were observed in at least three time periods after the switch. Significant (P < 0·01) improvement in PASI, DLQI and EQ-5D scores was observed 3–5 months after the switch and sustained under the whole observation period. The mean PASI, DLQI and EQ-5D changed from 13·5 ± 9·1, 9·0 ± 8·1 and 0·74 ± 0·22, respectively, before the switch, to 4·0 ± 3·5, 3·7 ± 4·7 and 0·79 ± 0·21, respectively, 1–5 years after the switch.

Conclusions:
Biological treatment, as used in clinical practice, shows a stable long-term effectiveness in all the measured dimensions, PASI, DLQI and EQ-5D.

Source: onlinelibrary.wiley.com

*Funding: Swedish Board of Health and Welfare and the Swedish Association of Local Authorities and Regions

[Caroline]

Very positive and very important, this type of statistics.
Also interesting would be research in the average time a bio can be used, do anti bodies build up after a pause in the treatment and are there specific reasons why certain bio’s must be stopped.

Cancer risk for psoriasis patients using bio treatments is already a very good step in the right direction, also with a more or less promising outcome.